Want to see TSE:DMED full AI Analyst Report?
DMED Stock Chart & Stats
C$0.08
>-C$0.01(-9.09%)
At close: 4:00 PM EST
C$0.08
>-C$0.01(-9.09%)
Day’s Range― - ―
52-Week RangeC$0.03 - C$0.25
Previous CloseN/A
Volume362.26K
Average Volume (3M)717.73K
Market Cap
C$5.92M
Enterprise ValueC$4.47M
Total Cash (Recent Filing)C$128.41K
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta2.03
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding131,559,310
10 Day Avg. Volume538,664
30 Day Avg. Volume717,725
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-3.02
Price to Sales (P/S)0.00
P/FCF Ratio-1.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
FDA Orphan Drug DesignationThis designation provides tax credits and market exclusivity, enhancing DiagnaMed's ability to accelerate development programs and potentially improving its market position in rare disease therapeutics.
Hydrogen Technology CommercializationProgress in hydrogen technology can open new revenue streams and align with global low-carbon energy trends, strengthening DiagnaMed's market presence and operational capabilities.
Private Placement FundingThe funding supports R&D and commercialization efforts, potentially enhancing DiagnaMed's product offerings and market competitiveness in cleantech and life sciences sectors.
Bears Say
Zero RevenueThe inability to generate revenue indicates significant challenges in market penetration and product monetization, threatening long-term financial sustainability and growth potential.
Negative EquityNegative equity reflects financial distress and declining stability, limiting DiagnaMed's ability to invest in growth opportunities and potentially impacting its creditworthiness.
Negative Cash FlowInefficient cash management and lack of positive cash flow conversion from operations stress financial instability, hindering DiagnaMed's ability to fund operations and strategic initiatives.
DiagnaMed Holdings Corp. News
DMED FAQ
What was DiagnaMed Holdings Corp.’s price range in the past 12 months?
DiagnaMed Holdings Corp. lowest stock price was C$0.03 and its highest was C$0.25 in the past 12 months.
What is DiagnaMed Holdings Corp.’s market cap?
DiagnaMed Holdings Corp.’s market cap is C$5.92M.
When is DiagnaMed Holdings Corp.’s upcoming earnings report date?
DiagnaMed Holdings Corp.’s upcoming earnings report date is Aug 20, 2026 which is in 47 days.
How were DiagnaMed Holdings Corp.’s earnings last quarter?
DiagnaMed Holdings Corp. released its earnings results on May 29, 2026. The company reported -C$0.001 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.001.
Is DiagnaMed Holdings Corp. overvalued?
According to Wall Street analysts DiagnaMed Holdings Corp.’s price is currently Overvalued.
Does DiagnaMed Holdings Corp. pay dividends?
DiagnaMed Holdings Corp. does not currently pay dividends.
What is DiagnaMed Holdings Corp.’s EPS estimate?
DiagnaMed Holdings Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does DiagnaMed Holdings Corp. have?
DiagnaMed Holdings Corp. has 131,559,310 shares outstanding.
What happened to DiagnaMed Holdings Corp.’s price movement after its last earnings report?
DiagnaMed Holdings Corp. reported an EPS of -C$0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -9.091%.
Which hedge fund is a major shareholder of DiagnaMed Holdings Corp.?
Currently, no hedge funds are holding shares in TSE:DMED
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
DiagnaMed Holdings Corp.
Diagnamed Holdings Corp. engages in the development and commercialization of AI healthcare solutions. The company focuses on developing BRAIN AGE BRAIN HEALTH, a brain health AI platform leveraging that aims to predict and monitor brain age and provide actionable insights for mental health and neurodegenerative disorders. It has a collaboration agreement with EIREX for the development and commercialization of EIREX’s novel modular carbon-free technology that extracts hydrogen from water. Diagnamed Holdings Corp. is headquartered in Toronto, Canada.
Technical Analysis
Diagnos
―
Rocket Doctor AI
―
Comprehensive Healthcare Systems Inc
―
UniDoc Health Corp
―
PanGenomic Health, Inc. Class A
―
Options Prices
Currently, No data available
---